COVID-19 患者同时使用法匹拉韦和华法林后 INR 升高：病例报告。
Elevated INR in a COVID-19 patient after concomitant administration of favipiravir and warfarin: A case report.
机构信息
Department of Pharmacy, Nihon University Hospital, Tokyo, Japan.
Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, Japan.
出版信息
J Clin Pharm Ther. 2022 Mar;47(3):407-410. doi: 10.1111/jcpt.13499. Epub 2021 Aug 2.
Abstract
WHAT IS KNOWN AND OBJECTIVE
Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID-19). Warfarin has many drug interactions, but no interactions with favipiravir have been reported.
CASE SUMMARY
Our patient was taking warfarin for deep vein thrombosis. The international normalized ratio (INR) was stable (1.65 to 2.0); however, it increased to 4.63 after administering favipiravir. The patient had no other factors justifying this change.
WHAT IS NEW AND CONCLUSION
Favipiravir and warfarin might have previously unidentified drug interactions that elevated the INR. Therefore, INR must be closely monitored when they are concomitantly administered in COVID-19 patients.
摘要
已知和目的
非那韦是一种有前途的治疗 2019 年冠状病毒病（COVID-19）的候选药物。华法林有许多药物相互作用，但尚未报道与非那韦有相互作用。
病例摘要
我们的患者因深静脉血栓形成而服用华法林。国际标准化比值（INR）稳定（1.65 至 2.0）；然而，在给予非那韦后，它增加到 4.63。患者没有其他因素可以证明这种变化是合理的。
新内容和结论
非那韦和华法林可能存在以前未识别的药物相互作用，导致 INR 升高。因此，在 COVID-19 患者同时给药时，必须密切监测 INR。
相似文献
1
Elevated INR in a COVID-19 patient after concomitant administration of favipiravir and warfarin: A case report.
J Clin Pharm Ther. 2022 Mar;47(3):407-410. doi: 10.1111/jcpt.13499. Epub 2021 Aug 2.
2
Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants.
Front Pharmacol. 2023 May 19;14:1191608. doi: 10.3389/fphar.2023.1191608. eCollection 2023.
3
Potential Drug Interaction Between Favipiravir and Warfarin in Patients With COVID-19: A Real-World Observational Study.
J Clin Pharmacol. 2023 Mar;63(3):338-344. doi: 10.1002/jcph.2161. Epub 2022 Oct 17.
4
Supratherapeutic INR During Treatment With Nirmatrelvir/Ritonavir and Warfarin and Acute Illness With COVID-19: A Case Report.
J Pharm Pract. 2024 Dec;37(6):1414-1418. doi: 10.1177/08971900241257296. Epub 2024 May 27.
5
Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy.
J Thromb Thrombolysis. 2020 Aug;50(2):452-456. doi: 10.1007/s11239-019-02016-3.
6
A potential interaction between warfarin and atovaquone.
Ann Pharmacother. 2011 Jan;45(1):e3. doi: 10.1345/aph.1P491. Epub 2010 Dec 28.
7
Drug Interaction Between Favipiravir and Warfarin: A Case Series.
Hosp Pharm. 2024 Jun;59(3):264-271. doi: 10.1177/00185787231214428. Epub 2023 Dec 29.
8
Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.
Ann Pharmacother. 2011 Nov;45(11):e58. doi: 10.1345/aph.1Q242. Epub 2011 Oct 18.
9
Prescribers' behavior following below- versus above-range international normalized ratio values in warfarin-treated deep vein thrombosis patients.
Curr Med Res Opin. 2016 Jul;32(7):1213-5. doi: 10.1185/03007995.2016.1164678. Epub 2016 Mar 17.
10
Effect of stress on international normalized ratio during warfarin therapy.
Ann Pharmacother. 2002 Apr;36(4):617-20. doi: 10.1345/aph.1A263.
引用本文的文献
1
Drug Interaction Between Favipiravir and Warfarin: A Case Series.
Hosp Pharm. 2024 Jun;59(3):264-271. doi: 10.1177/00185787231214428. Epub 2023 Dec 29.
2
Drug Synergism of Anticancer Action in Combination with Favipiravir and Paclitaxel on Neuroblastoma Cells.
Medicina (Kaunas). 2023 Dec 30;60(1):82. doi: 10.3390/medicina60010082.
3
Elevated INR in a COVID-19 patient after concomitant administration of azvudine and anticoagulants.
Front Pharmacol. 2023 May 19;14:1191608. doi: 10.3389/fphar.2023.1191608. eCollection 2023.
本文引用的文献
1
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
Arch Virol. 2021 Mar;166(3):949-954. doi: 10.1007/s00705-021-04956-9. Epub 2021 Jan 25.
2
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
Int J Infect Dis. 2021 Feb;103:62-71. doi: 10.1016/j.ijid.2020.11.142. Epub 2020 Nov 16.
3
Favipiravir: A new and emerging antiviral option in COVID-19.
Med J Armed Forces India. 2020 Oct;76(4):370-376. doi: 10.1016/j.mjafi.2020.08.004. Epub 2020 Sep 2.
4
Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China.
Biosci Trends. 2020 Sep 21;14(4):285-289. doi: 10.5582/bst.2020.03086. Epub 2020 Apr 30.
5
COVID-19 diagnosis and management: a comprehensive review.
J Intern Med. 2020 Aug;288(2):192-206. doi: 10.1111/joim.13091. Epub 2020 May 13.
6
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.
Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21.
7
Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
Br J Clin Pharmacol. 2019 Jul;85(7):1454-1463. doi: 10.1111/bcp.13914. Epub 2019 Apr 16.
8
Clinical Importance of Drug-Drug Interaction Between Warfarin and Prednisolone and Its Potential Mechanism in Relation to the Niemann-Pick C1-Like 1-Mediated Pathway.
Circ J. 2019 Jan 25;83(2):471-480. doi: 10.1253/circj.CJ-18-0807. Epub 2018 Dec 18.
9
High INR on warfarin.
BMJ. 2015 Apr 9;350:h1282. doi: 10.1136/bmj.h1282.
10
Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis.
Drug Metab Dispos. 2014 Aug;42(8):1349-56. doi: 10.1124/dmd.114.058834. Epub 2014 May 30.
Zotero 插件